Human helminth therapy to treat inflammatory disorders- where do we stand?

被引:120
|
作者
Helmby, Helena [1 ]
机构
[1] London Sch Hyg & Trop Med, Dept Immunol & Infect, Fac Infect & Trop Dis, London WC1E 7HT, England
关键词
Helminths; Inflammation; Regulation; Autoimmunity; PLACEBO-CONTROLLED TRIAL; TRICHURIS-SUIS THERAPY; IMMUNE-RESPONSES; HOOKWORM INFECTION; PARASITE INFECTION; COMMUNITIES; PREVALENCE; PRODUCTS; DISEASE; ALLERGY;
D O I
10.1186/s12865-015-0074-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Parasitic helminths have evolved together with the mammalian immune system over many millennia and as such they have become remarkably efficient modulators in order to promote their own survival. Their ability to alter and/or suppress immune responses could be beneficial to the host by helping control excessive inflammatory responses and animal models and pre-clinical trials have all suggested a beneficial effect of helminth infections on inflammatory bowel conditions, MS, asthma and atopy. Thus, helminth therapy has been suggested as a possible treatment method for autoimmune and other inflammatory disorders in humans.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Human helminth therapy to treat inflammatory disorders- where do we stand?
    Helena Helmby
    BMC Immunology, 16
  • [2] Anti-Inflammatory Therapy in Coronary Artery Disease: Where Do We Stand?
    Rakocevic, Jelena
    Dobric, Milan
    Borovic, Milica Labudovic
    Milutinovic, Katarina
    Milenkovic, Sanela
    Tomasevic, Miloje
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2023, 24 (01)
  • [3] Translational perspectives to treat Epidermolysis bullosa-Where do we stand?
    Prodinger, Christine
    Bauer, Johann W.
    Laimer, Martin
    EXPERIMENTAL DERMATOLOGY, 2020, 29 (11) : 1112 - 1122
  • [4] Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?
    Sagris, Marios
    Theofilis, Panagiotis
    Antonopoulos, Alexios S.
    Oikonomou, Evangelos
    Tsioufis, Kostas
    Tousoulis, Dimitris
    BIOMEDICINES, 2022, 10 (02)
  • [5] Rye and health - Where do we stand and where do we go?
    Jonsson, Karin
    Andersson, Roger
    Knudsen, Knud Erik Bach
    Hallmans, Goran
    Hanhineva, Kati
    Katina, Kati
    Kolehmainen, Marjukka
    Kyro, Cecilie
    Langton, Maud
    Nordlund, Emilia
    Laerke, Helle Nygaard
    Olsen, Anja
    Poutanen, Kajsa
    Tjonneland, Anne
    Landberg, Rikard
    TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
  • [6] Helminths, allergic disorders and IgE-mediated immune responses: Where do we stand?
    Erb, Klaus J.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (05) : 1170 - 1173
  • [7] Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?
    Barbullushi, Kordelia
    Rampi, Nicolo
    Serpenti, Fabio
    Sciume, Mariarita
    Fabris, Sonia
    De Roberto, Pasquale
    Fracchiolla, Nicola Stefano
    CANCERS, 2022, 14 (12)
  • [8] Antiangiogenics therapy for epithelial ovarian cancer: Where do we stand?
    de Cock, L.
    Leblanc, J.
    Kurtz, J. -E.
    ONCOLOGIE, 2014, 16 (06) : 318 - 324
  • [9] Treatment of negative symptoms: Where do we stand, and where do we go?
    Aleman, Andre
    Lincoln, Tania M.
    Bruggeman, Richard
    Melle, Ingrid
    Arends, Johan
    Arango, Celso
    Knegtering, Henderikus
    SCHIZOPHRENIA RESEARCH, 2017, 186 : 55 - 62
  • [10] Phytotherapy for Cachexia: Where Do We Stand?
    Kuchta, Kenny
    Cameron, Silke
    FRONTIERS IN PHARMACOLOGY, 2020, 11